Green Cross seeking free supply of Peramir

Published: 2009-11-25 06:58:00

Updated: 2009-11-25 06:58:00

Green Cross Corporation is considering offering an investigational antiviral drug Peramivir intravenous (IV) for the treatment of certain adult and pediatric patients with confirmed or suspected H1N1 influenza infection who are admitted to a hospital.

Green Cross said Peramivir will be distrib...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK